Monday, Apr 30, 2018 9:00a -
Wednesday, May 02, 2018 4:30p
Sheraton Boston Hotel
39 Dalton Street
Boston, MA 02199
$ 0 - 3997
Lectures & Conferences
Dedicated to Realizing the Commercial Potential of Gene Therapies
The closing weeks of 2017 marked a historic approval for Spark Therapeutics and a watershed moment for the reinvigorated gene therapy field. This first will undoubtedly not be the last time that gene therapies have a huge impact on rare disease sufferers.
Gene Therapy for Rare Disorders 2018 will equip you with the insights to make the most of this unprecedented opportunity. Rather than attempting to cover the entire cell and gene therapy world, this meeting will focus specifically on the critical clinical, manufacturing, regulatory and reimbursement challenges involved in delivering gene therapies to market.
Leaders from the likes of Spark, FDA, Pfizer, GSK and Bluebird Bio will deliver in-depth insights into the work that has underpinned their success, enabling you to maximize the commercial potential of your gene therapy products.
Join your colleagues at this uniquely focused event to ensure you’re making the right decisions with your gene therapy pipeline at such a pivotal time for the field.
Early booking discounts are available in addition to group rates. For more information, visit the website.
Conference + 2 Workshops: USD 3997
Conference + 1 Workshop: USD 3398
Conference Only: USD 2799
Workshop Only: USD 699
Focus Evening: USD 0
Speakers: Katherine High (Spark Therapeutics), Philip Gregory (Bluebird Bio), Steven Paul (Voyager Therapeutics), Jude Samulski (Pfizer), Steven Zelenkofske (uniQure), Mary Dunkle (NORD), Sven Kili (GSK), Olivier Danos (REGENXBIO), and Gumei Liu (FDA)